The results show that ASC‐J9® can suppress the Sorafenib‐induced p‐STAT3 expression in an AR‐independent manner, and the combined Sorafenib and ASC‐J9® treatment yields better suppression of HCC progression. Here, STAT3 is linked to hepatocellular carcinoma.